CR20150303A - Composiciones que comprenden vortioxetina y donepezilo - Google Patents

Composiciones que comprenden vortioxetina y donepezilo

Info

Publication number
CR20150303A
CR20150303A CR20150303A CR20150303A CR20150303A CR 20150303 A CR20150303 A CR 20150303A CR 20150303 A CR20150303 A CR 20150303A CR 20150303 A CR20150303 A CR 20150303A CR 20150303 A CR20150303 A CR 20150303A
Authority
CR
Costa Rica
Prior art keywords
compositions
vortioxetina
donepezilo
vortioxetine
donepezil
Prior art date
Application number
CR20150303A
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CR20150303A publication Critical patent/CR20150303A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden vortioxetina y donepezilo y el uso de una composición de este tipo para el tratamiento de disfunciones cognitivas.
CR20150303A 2012-12-13 2015-06-09 Composiciones que comprenden vortioxetina y donepezilo CR20150303A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13
PCT/EP2013/076337 WO2014090929A1 (en) 2012-12-13 2013-12-12 Compositions comprising vortioxetine and donepezil

Publications (1)

Publication Number Publication Date
CR20150303A true CR20150303A (es) 2016-07-07

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150303A CR20150303A (es) 2012-12-13 2015-06-09 Composiciones que comprenden vortioxetina y donepezilo

Country Status (44)

Country Link
US (1) US9211288B2 (es)
EP (1) EP2931276B1 (es)
JP (1) JP6257641B2 (es)
KR (1) KR102171152B1 (es)
CN (1) CN104853755B (es)
AP (1) AP2015008498A0 (es)
AR (2) AR093939A1 (es)
AU (1) AU2013357308B2 (es)
BR (1) BR112015013675B1 (es)
CA (1) CA2893468C (es)
CL (1) CL2015001615A1 (es)
CR (1) CR20150303A (es)
CY (1) CY1120098T1 (es)
DK (1) DK2931276T3 (es)
DO (1) DOP2015000133A (es)
EA (1) EA028300B1 (es)
EC (1) ECSP15023182A (es)
ES (1) ES2663680T3 (es)
GE (1) GEP201706739B (es)
GT (1) GT201500143A (es)
HK (1) HK1212601A1 (es)
HR (1) HRP20180333T1 (es)
HU (1) HUE036280T2 (es)
IL (1) IL239192B (es)
LT (1) LT2931276T (es)
MA (1) MA38253B1 (es)
ME (1) ME03029B (es)
MX (1) MX362886B (es)
MY (1) MY171802A (es)
NI (1) NI201500078A (es)
NO (1) NO2970700T3 (es)
NZ (1) NZ708595A (es)
PE (1) PE20151026A1 (es)
PH (1) PH12015501302B1 (es)
PL (1) PL2931276T3 (es)
PT (1) PT2931276T (es)
RS (1) RS56949B1 (es)
RU (1) RU2635528C2 (es)
SG (1) SG11201504483YA (es)
SI (1) SI2931276T1 (es)
TN (1) TN2015000235A1 (es)
UA (1) UA114016C2 (es)
WO (1) WO2014090929A1 (es)
ZA (1) ZA201504274B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
DK3528811T3 (da) 2017-03-30 2021-09-27 Rundle Res Llc Vortioxetin og mao-inhibitorer til behandling af depression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
AU632458B2 (en) 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (es) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
CA2252039C (en) 1996-04-12 2002-12-24 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ATE382036T1 (de) 2002-03-29 2008-01-15 Eisai R&D Man Co Ltd (1-indanon)-(1,2,3,6-tetrahydropyridin)derivat
DK1509232T3 (da) * 2002-05-31 2009-02-23 Lundbeck & Co As H Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
NZ572809A (en) * 2006-05-08 2011-02-25 Teikoku Seiyaku Kk Transdermally absorbable preparation comprising anti-dementia agent
CN101466365A (zh) * 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
RU2015122256A (ru) 2017-01-16
MA38253B1 (fr) 2017-10-31
CL2015001615A1 (es) 2015-08-07
CA2893468A1 (en) 2014-06-19
HK1212601A1 (zh) 2016-06-17
AR093939A1 (es) 2015-07-01
PL2931276T3 (pl) 2018-06-29
UA114016C2 (xx) 2017-04-10
SG11201504483YA (en) 2015-07-30
EA028300B1 (ru) 2017-10-31
EA201590932A1 (ru) 2015-10-30
ME03029B (me) 2018-10-20
ES2663680T3 (es) 2018-04-16
MY171802A (en) 2019-10-30
US9211288B2 (en) 2015-12-15
PE20151026A1 (es) 2015-07-11
AP2015008498A0 (en) 2015-05-31
ECSP15023182A (es) 2015-12-31
PH12015501302A1 (en) 2016-02-01
AR125920A2 (es) 2023-08-23
SI2931276T1 (en) 2018-05-31
NZ708595A (en) 2019-06-28
BR112015013675B1 (pt) 2022-04-26
IL239192A0 (en) 2015-07-30
LT2931276T (lt) 2018-04-10
CN104853755A (zh) 2015-08-19
NI201500078A (es) 2016-02-15
CA2893468C (en) 2021-01-12
MX2015007269A (es) 2015-08-12
JP6257641B2 (ja) 2018-01-10
KR20150095681A (ko) 2015-08-21
RS56949B1 (sr) 2018-05-31
DOP2015000133A (es) 2015-11-30
US20150297585A1 (en) 2015-10-22
JP2016502990A (ja) 2016-02-01
ZA201504274B (en) 2016-11-30
HRP20180333T1 (hr) 2018-04-06
WO2014090929A1 (en) 2014-06-19
MA38253A1 (fr) 2017-02-28
GEP201706739B (en) 2017-09-25
IL239192B (en) 2019-03-31
AU2013357308A1 (en) 2015-06-18
PH12015501302B1 (en) 2016-02-01
CY1120098T1 (el) 2018-12-12
CN104853755B (zh) 2017-08-22
NO2970700T3 (es) 2018-05-26
EP2931276A1 (en) 2015-10-21
AU2013357308B2 (en) 2017-08-31
MX362886B (es) 2019-02-22
BR112015013675A2 (pt) 2017-07-11
TN2015000235A1 (en) 2016-10-03
KR102171152B1 (ko) 2020-10-29
PT2931276T (pt) 2018-03-19
RU2635528C2 (ru) 2017-11-13
DK2931276T3 (en) 2018-03-26
HUE036280T2 (hu) 2018-06-28
EP2931276B1 (en) 2018-02-21
GT201500143A (es) 2016-01-22

Similar Documents

Publication Publication Date Title
CR20150303A (es) Composiciones que comprenden vortioxetina y donepezilo
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2014001065A1 (es) Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112017002090A2 (pt) formulação de fator viii